Effects of mepartricin, a polyene macrolide antibiotic, on estrogen-induced hyperplastic growth of the dorsolateral prostate and seminal vesicle in immature castrated rats

References

• Wendel EF, Brannen GE, Putong PB, Grayhack JT. The effect of orchiectomy and estrogens on benign prostatic hyperplasia. J Urol 1972; 108: 116–9
   PubMed Web of Science ®Google Scholar
• Walsh PC. Benign prostatic hyperplasia. Campbell's urology6th ed, PC Walsh, AB Retic, TA Stamey, ED Vaughan, Jr. WB Saunders, Philadelphia, PA 1992; 1009–27
   Google Scholar
• Mckeehan WL, Adams PS, Rosser MP. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free primary cell culture. Cancer Res 1984; 44: 1998–2010
   PubMed Web of Science ®Google Scholar
• McKeehan WL, Adams PS, Fast D. Different hormonal requirements for androgen-independent growth of normal and tumor epithelial cells from rat prostate. In Vitro Cell Dev Biol 1987; 23: 147–52
   PubMed Web of Science ®Google Scholar
• Griffiths K, Eaton CL, Harper ME, Peeling B, Davies P. Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur Urol 1991; 20(Suppl 2)68–77
   PubMedGoogle Scholar
• Skoldefors H, Blomstedt B, Carlstrom K. Serum hormone levels in benign prostatic hyperplasia. Scand J Urol Nephrol 1978; 12: 111–4
   PubMed Web of Science ®Google Scholar
• Kozak I, Bartsch W, Krieg M, Voigt KD. Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia. Prostate 1982; 3: 433–8
   PubMed Web of Science ®Google Scholar
• Walsh PC, Wilson JD. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976; 57: 1093–7
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ito K, Tamura Y, Suzuki T, Honma S, Yamanaka H, et al. Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings. Prostate 1996; 28: 328–37
   PubMed Web of Science ®Google Scholar
• Yuasa H, Fukabori Y, Mashimo T, Ohma C, Suzuki T, Yamanaka H, et al. The characteristics of hormone responsiveness of glandular epithelium and stroma in male accessory sex organs. Acta Urol Jpn 1993; 39: 631–7
   PubMedGoogle Scholar
• De Bernardi M, Rollero M, Goi A. Morphologic controls of prostatic gland after treatment with mepartricin: a histopathological study in the dog. Acta Toxico Ther 1986; 7: 13–9 (in Italian)
   Google Scholar
• Yoshinaka Y, Kobayashi H, Kirihara J, Sato F, Shakutou S, Yamanaka H. Effects of mepartricin (S-160) on spontaneous canine benign prostatic hyperplasia. Eur Urol 2000; 37: 428–35
   PubMed Web of Science ®Google Scholar
• Shakutou S, Bandoh K, Yoshinaka Y, Kobayashi H, Yamanaka H. Effects of mepartricin, a polyene macrolide agent, on fecal excretion and serum concentration of estrogen and number of prostatic estrogen receptors in immature rats. Prostate 1999; 38: 17–27
   PubMed Web of Science ®Google Scholar
• Suzuki H, Nakada T. Alteration of collagen biosynthesis and analysis of type I and type III collagens of prostate in young rats following sex hormone treatments. Arch Androl 1996; 36: 205–16
   PubMed Web of Science ®Google Scholar
• Nishi N, Matuo Y, Muguruma Y, Yoshitake Y, Nishikawa K, Wada F. A human prostatic growth factor (hPGF): partial purification and characterization. Biochem Biophys Res Commun 1985; 132: 1103–9
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RG. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–75
   PubMed Web of Science ®Google Scholar
• Franks, LM. Benign prostatic hypertrophy: gross and microscopic anatomy. Department of Health Education and Welfare, NIH Publication No.76-1113: 63, 1976.
   Google Scholar
• Mariotti A, Thornton M, Mawhinney M. Actions of androgen and estrogen on collagen levels in male accessory sex organs. Endocrinology 1981; 109: 837–43
   PubMed Web of Science ®Google Scholar
• Kozak I, Bartsch W, Krieg M, Voigt KD. Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia. Prostate 1982; 3: 433–8
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ito K, Suzuki T, Honma S, Yamanaka H. Synergistic effects of estrogen and androgen on the prostate: effects of estrogen on androgen- and estrogen-receptors, BrdU uptake, immunohistochemical study of AR, and responses to antiandrogens. Prostate 1995; 26: 151–63
   PubMed Web of Science ®Google Scholar
• Brolin J, Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992; 20: 281–95
   PubMed Web of Science ®Google Scholar
• Steiner MS. Role of peptide growth factors in the prostate: a review. Urology 1993; 42: 99–110
   PubMed Web of Science ®Google Scholar
• Mckeehan WL, Kan M, Hou J, Wang F, Adams P, Mansson PE. Heparin-binding (fibroblast) growth factor/receptor gene expression in the prostate. Molecular and cellular biology of prostate cancer, JP Karr, DS Coffey, RG Smith, DJ Tindall. Plenum Press, New York 1991; 115–26
   Google Scholar
• Shida K. Fundamental and clinical study on antiandrogens—androgen-dependency of prostatic tumors and clinical application of antiandrogens. Horumon To Rinsho 1980; 28: 899–928 (in Japanese)
   PubMedGoogle Scholar
• Takezawa Y, Fukabori Y, Yamanaka H, Mieda M, Honma S, Kushitani M, et al. Effects of the new steroidal antiandrogen TZP-4238 on hormone-induced canine prostatic hyperplasia. Prostate 1992; 21: 315–29
   PubMed Web of Science ®Google Scholar
• Harada M, Kinoshita Y, Moriyama M, Kondo I, Nakahashi M, Kumagai H, et al. Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA). Prostate 1994; 25: 147–55
   PubMed Web of Science ®Google Scholar